Go to the list of all blogs
AI dvisor's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
VEEV vs WAY: Weighing Two Healthcare Software Stocks

VEEV vs WAY: Weighing Two Healthcare Software Stocks

Key Takeaways

  • VEEV is a large-cap life sciences cloud software leader with roughly $50 billion in market capitalization, while WAY is a smaller healthcare payments software provider valued near $5.5 billion, placing them in very different stages of scale and maturity.
  • Recent momentum has diverged sharply: VEEV has posted strong gains over recent months, while WAY shares retreated after softer forward guidance despite solid quarterly results.
  • The two companies serve different ends of the healthcare software market, with VEEV focused on pharmaceutical R&D and commercial workflows and WAY on provider revenue-cycle and payment automation.
  • Tickeron AI Verdict: VEEV is the ticker of choice in this comparison, reflecting more consistent trend strength, greater scale, and more favorable relative market positioning over the recent period.
  • For deeper context, explore VEEV Major News and VEEV Today's Price Move, as well as WAY Major News and WAY Today's Price Move.
  • To see how automated strategies are currently positioning across the market, explore Trending AI Robots.

Introduction

Investors comparing healthcare technology names often weigh established platforms against smaller, higher-growth options. This look at VEEV and WAY highlights that contrast. Veeva Systems stands out as a leading provider of cloud software for life sciences, while Waystar Holding focuses on payments and revenue-cycle tools for healthcare providers. Both rely on recurring subscription revenue and are incorporating artificial intelligence, yet their sizes, growth trajectories, and recent market behavior set them apart. I also checked relative positioning using Tickeron’s AI Screener to round out the picture.

VEEV Overview and Recent Performance

VEEV (Veeva Systems Inc.) delivers cloud-based software and data solutions for pharmaceutical, biotechnology, and life sciences firms, covering CRM, content management, clinical data, regulatory, and quality processes. It operates at meaningful scale, with a market capitalization near $50 billion and a profitable, cash-generative subscription model.

Over the past several months, VEEV shares have shown clear strength, rising notably over the trailing three-month window and holding well above their 52-week lows. Positive sentiment has been reinforced by ongoing AI product updates, including tools to speed clinical study setup and manage safety reports, along with several analyst target increases. While revenue growth has moderated from a larger base and the company continues migrating CRM customers to the Vault platform, the stock’s relative performance has stayed positive.

WAY Overview and Recent Performance

WAY (Waystar Holding Corp.) offers cloud software that streamlines healthcare payments and revenue-cycle management for providers, patients, and payers. Based in Lehi, Utah, the company carries a market capitalization of roughly $5.5 billion and maintains high margins with strong cash generation.

Recent weeks have brought more mixed price action for WAY. The firm posted about 21% year-over-year revenue growth, with adjusted EBITDA margins in the mid-40% range, its largest client win to date, and net revenue retention of 108%. Still, the stock pulled back after management provided forward revenue guidance that pointed to a slower near-term pace, citing extended implementation timelines for its AI-driven offerings. This mix of solid underlying demand and tempered growth expectations has left sentiment and relative performance more uneven.

Head-to-Head Comparison

Although both operate in healthcare software, their models and risk profiles differ in important ways. VEEV functions as a broad, dominant platform serving life sciences clients across commercial and R&D areas, supported by deep regulatory knowledge and cross-selling potential. Its size underpins strong profitability and a conservative balance sheet, though the mature base translates to slower percentage growth and a valuation that offers limited margin for error.

WAY, on the other hand, is a smaller, more focused player in revenue-cycle and payment automation. It is expanding revenue more quickly than VEEV and enjoys attractive margins, yet it contends with longer contract ramps, greater dependence on AI adoption for acceleration, and elevated short interest. These differences create distinct trade-offs: VEEV provides stability and established leadership, while WAY presents a higher-growth, higher-beta profile with added near-term guidance uncertainty.

Tickeron AI Verdict

Considering factors such as trend consistency, relative momentum, scale, and market positioning, Tickeron’s AI currently points to VEEV in this matchup. Veeva’s sustained upward price move, solid profitability, and steady product catalysts have aligned with stronger relative performance, whereas Waystar’s softer forward guidance and extended revenue ramps add more near-term variability. This reflects a probabilistic view of current conditions rather than a firm forecast and should be considered alongside individual research and risk tolerance.

AI-Powered Trading Insights

In my research process, I frequently review Tickeron’s AI Trading Bots to see how systematic strategies are positioned around individual names. The platform curates a selection of bots across styles, timeframes, and performance metrics, offering a practical way to cross-check manual analysis with automated signals that update with live market data.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VEEV, WAY

Momentum Indicator for VEEV turns negative, indicating new downward trend

VEEV saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In 54 of the 78 cases, the stock moved further down in the following days. The odds of a decline are at 69%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for VEEV turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 31 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.

VEEV moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in 179 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

VEEV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 133 of 210 cases where VEEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.617) is normal, around the industry mean (4.523). VEEV has a moderately high P/E Ratio (48.989) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (1.248) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.739) is also within normal values, averaging (6.105).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was 5%. DH experienced the highest price growth at 5%, while DRIO experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 20% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 54
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: 0 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of industry-specific, cloud-based software solutions for the life sciences industry

Industry ServicestotheHealthIndustry

Industry
Packaged Software
Address
4280 Hacienda Drive
Phone
+1 925 452-6500
Employees
7928
Web
https://www.veeva.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.